Trial Profile
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2021
Price :
$35
*
At a glance
- Drugs Azithromycin (Primary) ; Fluticasone propionate (Primary) ; Montelukast (Primary)
- Indications Bacterial infections; Bronchiolitis obliterans
- Focus Therapeutic Use
- Acronyms FAM for BOS
- 01 Sep 2021 Results of an analysis assessing the biomarkers associated with Bronchiolitis obliterans syndrome diagnosis after lung transplantation are also associated with Bronchiolitis obliterans syndrome diagnosis after allogeneic HCT ( a data from who participated in a phase II multicenter study of FAM treatment (NCT01307462) and control from (NCT00637689 and NCT01902576)) published in the Transplantation and Cellular Therapy
- 22 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 04 Jun 2013 Planned End Date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov.